<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111693</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-312</org_study_id>
    <secondary_id>2014-A00975-42</secondary_id>
    <nct_id>NCT03111693</nct_id>
  </id_info>
  <brief_title>CT Evaluation of Cardiovascular Risk Markers in Obese Patients</brief_title>
  <acronym>RisqOScan</acronym>
  <official_title>CT Evaluation of Cardiovascular Risk Markers in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a chronic metabolic disorder : it leads to coronary heart disease and early&#xD;
      atherosclerosis.&#xD;
&#xD;
      Coronary artery calcium measured by CT is known as a robust predictor to predict risk for&#xD;
      cardiac events in symptomatic and asymptomatic individuals. Furthermore, recent studies show&#xD;
      that other CT risk factor exists, independent of calcium scoring, such as epicardial fat,&#xD;
      intrathoracic fat and visceral fat.&#xD;
&#xD;
      The aim of this prospective study is to evaluate these new cardiovascular risk markers in&#xD;
      obese patients, using standard dose CT and low dose CT with adaptative statistical iterative&#xD;
      reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective single-center study, obese patients of our clinical nutrition service,&#xD;
      hospitalized for nutritional assessement, are included.&#xD;
&#xD;
      All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT&#xD;
      750 HD scanner, GE Healthcare), using prospective ECG-triggerring. The investigation protocol&#xD;
      began with a standard-dose acquisition followed immediately by a low-dose acquisition,&#xD;
      recorded over strictly identical segments (identical first and last sections).&#xD;
&#xD;
      After these two examinations, estimated dose values are less than the diagnostic scan&#xD;
      reference level for a coroCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epicardial fat evaluation in obese population</measure>
    <time_frame>at day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium scoring evaluation</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Epicardial Fat</condition>
  <condition>Obesity</condition>
  <condition>Cardiovascular Risks Markers</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Low Dose Computed Tomography</condition>
  <arm_group>
    <arm_group_label>obese patients</arm_group_label>
    <description>obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unenhanced Coro-CT</intervention_name>
    <description>All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.</description>
    <arm_group_label>obese patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        obese population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  obesity &gt;30 indicated non enhanced coroCT for calcium scoring.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 ans&#xD;
&#xD;
          -  low Framingham scoring&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  not providing informed consent&#xD;
&#xD;
          -  history of cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucie CASSAGNES</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Lucie CASSAGNES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epicardial fat</keyword>
  <keyword>Obesity</keyword>
  <keyword>Cardiovascular risks markers</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Low dose computed tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

